Novo Nordisk A/S (NVO): Did This GLP-1 and Weight Loss Stock Receive a Good Rating from Analysts?

More than one billion people worldwide are obese , including 650 million adults, 340 million adolescents, and 39 million children.

A brand-new class of weight-loss drugs that don't require diets or intense exercise appears to be revolutionary.

With the help of these revolutionary drugs, overweight and obese individuals can reduce their body weight by 15% to 20% .

Morgan Stanley Research projects that the global obesity drugs market will reach $105 billion in 2030 .

The obesity drugs market is a high-growth industry and since it's in its early innings, now may be a time to add some weight loss stocks to your watchlists.

Denmark -based Novo Nordisk A/S ( NYSE : NVO ) is a renowned healthcare company that was established in 1923 .

Ozempic and Wegovy are in high demand on the market, which is fueling this expansion.

The company is a leader in the treatment of diabetes and played a significant role in the development of insulin pens.

Novo Nordisk ranks 5th on our list of the best GLP-1 and weight loss stocks to buy.

NVO is a buy due to its positive financial outlook, strategic ambitions, and strong historical performance.